

1           **NATIONAL INSTITUTE FOR HEALTH AND CARE**  
2   **EXCELLENCE**

3   **Guideline**

4           **Pelvic floor dysfunction: prevention and non-**  
5   **surgical management**

6   **Draft for consultation, June 2021**

**This guideline covers** the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It recommends interventions based on the specific symptoms women are experiencing (such as urinary or faecal incontinence), to ensure they get the best possible support. The guideline aims to raise awareness of the condition, so that women understand how to reduce their risk of pelvic floor dysfunction and women with symptoms are aware of the benefits and drawbacks of all non-surgical management options.

**Who is it for?**

- Healthcare professionals
- Commissioners and providers
- Education providers
- Women using services, and their families and carers.

**What does it include?**

- the recommendations
- recommendations for research
- rationale and impact sections that explain why the committee made the recommendations and how they might affect practice
- the guideline context.

Information about how the guideline was developed is on the [guideline's webpage](#). This includes the evidence reviews, the scope, details of the committee and any declarations of interest.

This guideline uses the term 'women' throughout, but this should be taken to include those who do not identify as women but who have female pelvic organs.

1

2

1 **Contents**

2

3 Recommendations ..... 4

4 1.1 Raising awareness of pelvic floor dysfunction for all women ..... 4

5 1.2 Risk factors for pelvic floor dysfunction ..... 7

6 1.3 Preventing pelvic floor dysfunction ..... 9

7 1.4 Communicating and providing information to women with pelvic floor

8 dysfunction ..... 12

9 1.5 Assessment in primary care ..... 14

10 1.6 Non-surgical management of pelvic floor dysfunction ..... 16

11 Recommendations for research ..... 23

12 Rationale and impact..... 31

13 Context..... 53

14 Finding more information and resources ..... 54

15

## 1 Recommendations

People have the right to be involved in discussions and make informed decisions about their care, as described in [NICE's information on making decisions about your care](#).

[Making decisions using NICE guidelines](#) explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

2 'Pelvic floor dysfunction' covers a variety of symptoms and disorders. This guideline  
3 covers the following symptoms and disorders, when they are associated with pelvic  
4 floor dysfunction:

- 5 • urinary incontinence
- 6 • emptying disorders of the bladder
- 7 • faecal incontinence
- 8 • emptying disorders of the bowel
- 9 • pelvic organ prolapse
- 10 • sexual dysfunction
- 11 • chronic pelvic pain.

12 The 3 most common and definable symptoms are urinary incontinence, faecal  
13 incontinence and pelvic organ prolapse.

### 14 **1.1 Raising awareness of pelvic floor dysfunction for all** 15 **women**

16 1.1.1 When producing resources on pelvic floor dysfunction, include:

- 17 • the symptoms of pelvic floor dysfunction
- 18 • visual aids to help identify potential causes of symptoms (for example,  
19 by showing the anatomy of pelvic organs)
- 20 • when to get help

- 1           • where to go for help (including self-referral to community-based  
2           multidisciplinary teams, where available)
- 3           • an outline of risk factors, prevention and management options  
4           (including non-surgical management and lifestyle changes).
- 5 1.1.2    Consider providing information on pelvic floor dysfunction in the following  
6           formats and settings:
- 7           • Formats
- 8           – magazine adverts
- 9           – leaflets in the community (for example at GP surgeries, family  
10          planning clinics and exercise classes)
- 11          – videos and information on social media
- 12          – interactive online tools (for example the NHS app).
- 13          • Settings
- 14          – as part of general exercise programmes
- 15          – in leaflets on gynaecological cancer treatment or hysterectomy
- 16          – contact with a healthcare practitioner with pelvic floor dysfunction  
17          knowledge
- 18          – giving advice to people with contacts in the community (such as  
19          exercise instructors and teachers), so they can provide information  
20          on pelvic floor dysfunction themselves
- 21          – on community and health trust websites
- 22          – information provided by healthcare charities
- 23          – covering pelvic floor dysfunction in the syllabus for trainee nurses,  
24          physiotherapists, doctors, midwives and teachers.
- 25 1.1.3    Tailor information about pelvic floor dysfunction for different age groups  
26           and characteristics (for example pregnancy).
- 27 1.1.4    Local authorities should consider designing pelvic floor dysfunction  
28           information programmes for specific communities when there is evidence  
29           of healthcare inequalities (for example access to services). This can be  
30           done by:

- 1           • finding more effective ways to provide information (for example by  
2           attending community meetings)
- 3           • involving members of the community as champions
- 4           • using webinars to reach women who are unable to attend meetings in  
5           person.
- 6    1.1.5    For women using maternity services, include information on pelvic floor  
7           dysfunction symptoms and how to access local services:
- 8           • in the booking information pack or patient portal
- 9           • at all midwife consultations and reviews.
- 10   1.1.6    Health visitors, midwives and GPs should discuss pelvic floor dysfunction  
11           with women at each postnatal contact.
- 12   1.1.7    Teach young women (between 12 and 17 years) in school about pelvic  
13           floor anatomy, pelvic floor muscle exercises and how to prevent pelvic  
14           floor dysfunction.
- 15   1.1.8    Provide information on pelvic floor dysfunction for older women within  
16           primary and intermediate care services, and within care homes and  
17           supported living communities. This could be done:
- 18           • when women ask for advice about menopause
- 19           • as part of general health assessments
- 20           • as part of comprehensive geriatric health assessments.
- 21   1.1.9    For guidance on tailoring communication, information and shared decision  
22           making for people using health and social care services, see:
- 23           • the [NICE guideline on patient experience in adult NHS services](#)
- 24           • the [NICE guideline on people's experience in adult social care services](#)
- 25           • the [NHS Accessible Information Standard](#) (in particular for guidance on  
26           making information accessible).

- 1 1.1.10 For guidance on planning and developing digital and mobile tools to  
2 provide tailored information, see the [NICE guideline on behaviour change:  
3 \[digital and mobile health interventions\]\(#\)](#).

For a short explanation of why the committee made these recommendations see the [rationale and impact section on raising awareness of pelvic floor dysfunction for all women](#).

Full details of the evidence and the committee's discussion are in [evidence review A: raising awareness of pelvic floor dysfunction](#).

- 4 **1.2 Risk factors for pelvic floor dysfunction**
- 5 1.2.1 When discussing the risk of pelvic floor dysfunction with women, advise  
6 them that their risk is higher with any of the characteristics in box 1.

## 1 **Box 1 Risk factors for pelvic floor dysfunction**

### **Modifiable risk factors**

- A body mass index (BMI) over 25 kg/m<sup>2</sup>
- Smoking
- Lack of exercise
- Constipation
- Diabetes

### **Non-modifiable risk factors**

- Age (risk increases with increasing age)
- Family history of urinary incontinence, overactive bladder or faecal incontinence
- Gynaecological cancer and any treatments for this
- Gynaecological surgery (such as a hysterectomy)
- Fibromyalgia
- Chronic respiratory disease and cough (chronic cough may increase the risk of faecal incontinence and flatus incontinence)

Related to pregnancy:

- Being over 30 years when having a baby
- Having had any children before their current pregnancy

Related to labour:

- Assisted vaginal birth (forceps or vacuum)
- A vaginal birth when the baby is lying face up (occipito-posterior)
- An active second stage of labour taking more than 1 hour
- Injury to the anal sphincter during birth.

2

- 3 1.2.2 For pregnant women with pelvic floor dysfunction that started before or  
4 during their pregnancy, advise them that there is an increased risk that  
5 their symptoms will get worse during their pregnancy and that they may  
6 persist after this (see the sections on [preventing pelvic floor dysfunction](#))



1 and [non-surgical management of pelvic floor dysfunction](#) for more  
2 guidance).

For a short explanation of why the committee made these recommendations see the [rationale and impact section on risk factors for pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in:

- [evidence review B: risk factors for pelvic floor dysfunction](#)
- [evidence review C: co-existing conditions](#)
- [evidence review D: prediction tools](#).

### 3 **1.3 Preventing pelvic floor dysfunction**

#### 4 **Exercise and diet**

5 1.3.1 Advise women that exercise and a healthy diet can help prevent pelvic  
6 floor dysfunction.

7 1.3.2 On levels of exercise, advise women to follow the standard advice, as  
8 covered by:

- 9 • the [UK Chief Medical Officers' physical activity guidelines](#)
- 10 • the [NICE guideline on physical activity: brief advice for adults in primary](#)  
11 [care](#)
- 12 • the [NICE guideline on physical activity: walking and cycling](#).

13 1.3.3 On diet, advise women to:

- 14 • have a balanced diet (following [Public Health England's Eatwell Guide](#)),  
15 and in particular to eat enough fibre, as this can improve stool  
16 consistency and prevent symptoms of faecal incontinence
- 17 • modify their fluid intake (increasing if it is too low, decreasing if it is too  
18 high).

19 1.3.4 For guidance on training to help health and social care practitioners  
20 recognise and respond to diet, exercise and hydration needs in older  
21 people with social care needs and multiple long-term conditions, see the

1 [section on training health and social care practitioners in the NICE](#)  
2 [guideline on older people with social care needs and multiple long-term](#)  
3 [conditions](#).

#### 4 **Weight loss, stopping smoking and managing diabetes**

5 1.3.5 For guidance on weight loss, see the [NICE guideline on managing](#)  
6 [obesity](#), and (if relevant) the [NICE guideline on weight management](#)  
7 [before, during and after pregnancy](#).

8 1.3.6 Give advice on stopping smoking, using the NICE guidelines on:

- 9 • [stop smoking interventions and services](#)
- 10 • [smoking: stopping in pregnancy and after childbirth](#)
- 11 • [smoking prevention in schools](#)
- 12 • [smoking: harm reduction](#).

13 1.3.7 For guidance on managing diabetes, see the NICE guidelines on:

- 14 • [type 1 diabetes in adults](#)
- 15 • [type 2 diabetes in adults](#)
- 16 • [diabetes \(type 1 and type 2\) in children and young people](#).

For a short explanation of why the committee made these recommendations see the [rationale and impact section on exercise and diet and other modifiable risk factors](#).

Full details of the evidence and the committee's discussion are in:

- [evidence review B: risk factors for pelvic floor dysfunction](#)
- [evidence review E: lifestyle factors for the prevention of pelvic floor dysfunction](#).

#### 17 **Pelvic floor muscle training**

##### 18 **All women**

19 1.3.8 Encourage women of all ages to do pelvic floor muscle training, and  
20 explain that it helps to prevent symptoms of pelvic floor dysfunction.

1 1.3.9 Encourage women to continue pelvic floor muscle training throughout their  
2 life, because long-term training continues to help prevent symptoms.

### 3 **During and after pregnancy**

4 1.3.10 Explain to women who are pregnant or who have recently given birth that  
5 pelvic floor muscle training helps prevent pelvic floor dysfunction.

6 1.3.11 Offer a 3-month programme of supervised pelvic floor muscle training:

- 7 • from week 20 of pregnancy, for pregnant women who have a first-  
8 degree relative with pelvic floor dysfunction
- 9 • during postnatal care, for women who have experienced any of the  
10 following risk factors during birth:
  - 11 – assisted vaginal birth (forceps or vacuum)
  - 12 – a vaginal birth when the baby is lying face up (occipito posterior)
  - 13 – injury to the anal sphincter.

14 1.3.12 Before discharging women from maternity services, and during routine  
15 postnatal care, encourage them to do pelvic floor muscle training.

16 1.3.13 When designing a pelvic floor muscle training programme, see the NICE  
17 guideline on behaviour change for relevant recommendations:

- 18 • [recommendation 7: use proven behaviour change techniques when](#)  
19 [designing interventions](#)
- 20 • [recommendation 8: ensure interventions meet individual needs.](#)

### 21 **Supervising pelvic floor muscle training**

22 1.3.14 Pelvic floor muscle training programmes should be supervised by a  
23 physiotherapist or other healthcare professional with the appropriate  
24 expertise in pelvic floor muscle training.

25 1.3.15 Supervision should involve:

- 26 • assessing the woman's ability to perform a pelvic floor contraction

- 1           • tailoring the pelvic floor muscle training programme to the woman's
- 2           ability to perform a pelvic floor contraction, any discomfort felt, and her
- 3           individual needs
- 4           • encouraging the woman to complete the course, because this will help
- 5           to prevent and manage symptoms.

For a short explanation of why the committee made these these recommendations see the [rationale and impact section on pelvic floor muscle training for preventing pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review F: pelvic floor muscle training to prevent pelvic floor dysfunction](#).

## 6   **1.4       Communicating and providing information to women with**

### 7           **pelvic floor dysfunction**

#### 8   **Communication**

- 9   1.4.1     Agree consultation formats (for example, in person, video or telephone)
- 10           with each woman with pelvic floor dysfunction, taking into account the
- 11           need for physical examinations.
  
- 12   1.4.2     When discussing pelvic floor dysfunction:
  
- 13           • be aware that women may feel embarrassed discussing their
- 14           symptoms, and they may believe that healthcare professionals will also
- 15           be embarrassed
- 16           • take particular care around terminology:
- 17           – for example, avoid using 'faeces' if a woman better understands
- 18           'poo'
- 19           – be aware that women may not know the precise technical terms for
- 20           parts of their pelvic anatomy, so may use incorrect terms
- 21           • tailor information to each woman's level of understanding of anatomy
- 22           and of the causes of pelvic floor dysfunction.

1 1.4.3 For general guidance on communicating with patients, see the  
2 [communication section in the NICE guideline on patient experience of](#)  
3 [adult NHS services](#).

4 1.4.4 When providing information to women with pelvic floor dysfunction and  
5 cognitive impairment, ask them if they want their family, carers and other  
6 people to be involved, to support them (as appropriate) and to help  
7 reinforce and support management plans.

## 8 **Information for women with pelvic floor dysfunction**

9 1.4.5 Help women with pelvic floor dysfunction to understand their condition by  
10 giving clear and concise information. This should include:

- 11 • the anatomy of the pelvic floor and pelvic organs (using visual aids  
12 when helpful)
- 13 • possible causes of their symptoms
- 14 • management options and possible outcomes
- 15 • an explanation that interventions will be focused on their symptoms,  
16 rather than on pelvic floor dysfunction in general
- 17 • other medical conditions and treatments that can cause or exacerbate  
18 their symptoms (see [risk factors for pelvic floor dysfunction](#)).

19 1.4.6 Tailor information to each woman's age, level of understanding and  
20 circumstances, because pelvic floor dysfunction can affect women  
21 differently at different stages of life. For example:

- 22 • young women (between 12 and 17 years)
- 23 • women who are pregnant or who have given birth
- 24 • women who have gone through menopause
- 25 • women with comorbidities or frailty.

26 1.4.7 Consider digital information sources, for example apps or videos, to  
27 support women with pelvic floor dysfunction (for guidance on developing  
28 digital tools, see the [NICE guideline on behaviour change: digital and](#)  
29 [mobile health interventions](#)).

For a short explanation of why the committee made these recommendations see the [rationale and impact section on communicating with and providing information to women with pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review G: information valued by women](#) and [evidence review H: effective ways of providing information](#).

## 1 1.5 Assessment in primary care

2 1.5.1 At initial assessment in primary care, take a general history from the  
3 woman about current and past symptoms or disorders associated with  
4 pelvic floor dysfunction, such as:

- 5 • urinary incontinence
- 6 • emptying disorders of the bladder
- 7 • faecal incontinence
- 8 • emptying disorders of the bowel
- 9 • pelvic organ prolapse
- 10 • sexual dysfunction
- 11 • chronic pelvic pain.

12 1.5.2 Depending on the symptoms described, carry out a focused history,  
13 clinical examination and investigations to exclude other causes, such as:

- 14 • pelvic masses
- 15 • neurological disease
- 16 • urinary tract infection
- 17 • adverse effects of medication
- 18 • diabetes
- 19 • cancer (for further information see the [NICE guideline on suspected](#)  
20 [cancer: recognition and referral](#))
- 21 • fistula
- 22 • inflammatory bowel or bladder conditions
- 23 • mobility and cognitive impairment.

1 1.5.3 Ask women who have recently given birth about symptoms of pelvic floor  
2 dysfunction during routine postnatal care, in hospital and in the  
3 community.

4 1.5.4 For woman who are taking multiple medications, conduct a medication  
5 review. For guidance on how to do this, see the [section on medication  
6 review in the NICE guideline on medicines optimisation](#).

7 1.5.5 Depending on the symptoms, consider other clinical examinations. For  
8 example:

- 9
- 10 • inspecting the woman's vulva and vagina for atrophy
  - 11 • asking them to bear down, to check for visible vaginal or rectal prolapse
  - 12 • rectal examination to check for impaction, for women at risk of this.

13 1.5.6 For more guidance on assessing urinary incontinence and pelvic organ  
14 prolapse, see the [NICE guideline on urinary incontinence and pelvic organ  
15 prolapse in women](#).

16 1.5.7 If the woman has symptoms of faecal incontinence, follow the  
17 [recommendations on baseline assessment in the NICE guideline on  
18 faecal incontinence](#).

For a short explanation of why the committee made this recommendation/these  
recommendations see the [rationale and impact section on assessment in primary  
care](#).

Full details of the evidence and the committee's discussion are in [evidence review  
I: assessment in non-specialist care](#) and [evidence review G: information valued by  
women](#).

18

## 1 **1.6 Non-surgical management of pelvic floor dysfunction**

### 2 **Community-based multidisciplinary teams**

3 1.6.1 Following initial assessment in primary care, consider a community-based  
4 multidisciplinary team approach for the management of pelvic floor  
5 dysfunction.

6 1.6.2 The community-based multidisciplinary team should have competencies  
7 related to assessing and managing pelvic floor dysfunction, such as:

- 8 • carrying out initial assessments (see the [section on assessment in](#)  
9 [primary care](#))
- 10 • awareness of the psychosocial implications of pelvic floor dysfunction
- 11 • identifying risk factors
- 12 • interpreting urinalysis
- 13 • conducting and interpreting bladder scans to measure post-void  
14 residual volume
- 15 • conducting routine digital assessments of the pelvic floor and pelvic  
16 floor muscle contractions
- 17 • training women and their families and carers in behavioural  
18 interventions for pelvic floor dysfunction (such as bladder retraining)
- 19 • prescribing and reviewing medications, and knowledge of interactions  
20 related to pelvic floor dysfunction
- 21 • supervising a pelvic floor muscle training programme (see the [section](#)  
22 [on supervising pelvic floor muscle training](#))
- 23 • managing the use of pessaries and intravaginal devices
- 24 • training other care providers to assess and manage pelvic floor  
25 dysfunction
- 26 • identifying which women need referral to specialist care.

27 1.6.3 Discuss and agree a management plan with women who have suspected  
28 or confirmed pelvic floor dysfunction.



For a short explanation of why the committee made these recommendations see the [rationale and impact section on community-based multidisciplinary teams](#).

Full details of the evidence and the committee's discussion are in [evidence review R: community-based multidisciplinary teams](#).

## 1 Lifestyle changes

### 2 Encouraging women to make lifestyle changes

3 1.6.4 When discussing lifestyle changes with women who have pelvic floor  
4 dysfunction:

- 5 • motivate them to make changes by focusing discussions on how this
- 6 will improve their symptoms
- 7 • give them regular encouragement to keep up the changes, because it
- 8 may take weeks or months before they notice a benefit.

For a short explanation of why the committee made this recommendation see the [rationale and impact section on encouraging women to make lifestyle changes](#).

Full details of the evidence and the committee's discussion are in [evidence review G: information valued by women](#).

## 9 Weight loss

10 1.6.5 Advise women with a body mass index (BMI) over 30 kg/m<sup>2</sup> that weight  
11 loss can help with the following symptoms associated with pelvic floor  
12 dysfunction:

- 13 • urinary incontinence
- 14 • overactive bladder
- 15 • pelvic organ prolapse.

16 1.6.6 For guidance on weight loss, see the [NICE guideline on managing](#)  
17 [obesity](#), and (if relevant) the [NICE guideline on weight management](#)  
18 [before, during and after pregnancy](#).

1 1.6.7 Refer women for weight loss support following the [NICE guideline on](#)  
2 [lifestyle services for weight management in overweight or obese adults](#)  
3 and the [NICE guideline on lifestyle services for weight management in](#)  
4 [overweight or obese children and young people](#).

5 1.6.8 Do not wait for women to lose weight before starting other pelvic floor  
6 dysfunction management options.

For a short explanation of why the committee made these recommendations see the [rationale and impact section on weight loss](#).

Full details of the evidence and the committee's discussion are in [evidence review J: weight loss interventions](#).

## 7 **Diet**

8 1.6.9 For all women with pelvic floor dysfunction:

- 9
- 10 • explain how a balanced diet (following [Public Health England's Eatwell](#)  
11 [Guide](#)) and appropriate fluid intake can improve stool consistency,  
12 which can help with their symptoms
  - 13 • follow guidance on maintaining healthy bowel habits in  
14 [recommendation 1.3.2 of the NICE guideline on faecal incontinence in](#)  
15 [adults](#) (including for women under 18 or with symptoms other than  
faecal incontinence).

16 1.6.10 Advise women with overactive bladder or urinary incontinence associated  
17 with pelvic floor dysfunction to:

- 18
- 19 • reduce their caffeine intake
  - 20 • modify their fluid intake (increasing if it is too low, decreasing if it is too  
high).

For a short explanation of why the committee made these recommendations see the [rationale and impact section on diet](#).

Full details of the evidence and the committee's discussion are in [evidence review K: dietary factors](#).

1 **Exercise**

2 1.6.11 For women who are doing supervised pelvic floor muscle training and  
3 want to exercise, advise them that supervised exercise (for example yoga  
4 or pilates classes) may help with their symptoms.

5 1.6.12 Advise women with pelvic floor dysfunction that there is no evidence that  
6 unsupervised exercise (such as walking or swimming) will improve or  
7 worsen their symptoms.

For a short explanation of why the committee made these recommendations see the [rationale and impact section on exercise](#).

Full details of the evidence and the committee's discussion are in [evidence review L: physical activity](#).

8 **Pelvic floor muscle training**

9 **For pelvic organ prolapse**

10 1.6.13 Consider a programme of supervised pelvic floor muscle training for at  
11 least 4 months for women with symptomatic pelvic organ prolapse that  
12 does not extend beyond the hymen upon straining.

13 **For stress urinary incontinence or mixed urinary incontinence**

14 1.6.14 Offer a programme of supervised pelvic floor muscle training for at least  
15 3 months to women (including pregnant women) with stress urinary  
16 incontinence or mixed urinary incontinence.

17 **For faecal incontinence with co-existing pelvic organ prolapse**

18 1.6.15 Consider a programme of supervised pelvic floor muscle training for at  
19 least 4 months for women with faecal incontinence and co-existing pelvic  
20 organ prolapse.

1 **Group and individual training**

2 1.6.16 For women who are doing a supervised pelvic muscle floor training  
3 programme, offer the choice of group or individual sessions.

4 **Supervising pelvic floor muscle training**

5 1.6.17 See [supervising pelvic floor muscle training](#) in the section on preventing  
6 pelvic floor dysfunction.

7 **Review**

8 1.6.18 When providing a programme of pelvic floor muscle training, offer at least  
9 1 review to assess progress during the programme, and 1 review at the  
10 end of the programme.

11 **Supplementing pelvic floor muscle training**

12 1.6.19 For women who are unable to perform an effective pelvic floor muscle  
13 contraction, consider supplementing pelvic floor muscle training with  
14 biofeedback, electrical stimulation or vaginal cones.

15 **Continuing pelvic floor muscle training**

16 1.6.20 If the programme is beneficial, advise women to continue pelvic floor  
17 muscle training after the supervised programme ends.

For a short explanation of why the committee made these recommendations see the [rationale and impact section on pelvic floor muscle training for managing pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review M: pelvic floor muscle training for management of pelvic floor dysfunction](#).

18 **Intravaginal devices and pessaries**

19 **Intravaginal devices for urinary incontinence**

20 1.6.21 Consider a trial of intravaginal devices for women with urinary  
21 incontinence, if other non-surgical options have been unsuccessful.

1 **Pessaries for symptomatic pelvic organ prolapse**

2 1.6.22 Consider pessaries for women who have symptomatic pelvic organ  
3 prolapse.

4 1.6.23 Before starting treatment with a pessary for women with symptomatic  
5 pelvic organ prolapse:

- 6 • discuss with the woman how a pessary could help, and explain it may  
7 not help with their urinary and bowel symptoms
- 8 • explain that a pessary will only help with their pelvic organ prolapse  
9 symptoms while it is in place, and the symptoms will come back when it  
10 is removed
- 11 • explain that reducing the prolapse with a pessary may cause new  
12 stress urinary incontinence.

13 See [recommendation 1.7.8 in the NICE guideline on urinary incontinence](#)  
14 [and pelvic organ prolapse](#) for further discussions to have with women  
15 before starting treatment with a pessary.

16 1.6.24 If women using a pessary experience new stress urinary incontinence,  
17 offer them a choice of treatment for the incontinence or removal of the  
18 pessary.

19 1.6.25 For more guidance on pessaries for women with symptomatic pelvic  
20 organ prolapse, see [the section on pessaries in the NICE guideline on](#)  
21 [urinary incontinence and pelvic organ prolapse](#).

22 **Review**

23 1.6.26 For women who are self-managing their intravaginal device or pessary,  
24 explain how they can seek advice from a healthcare provider if they have  
25 problems.

26 1.6.27 For guidance on reviewing pessaries for women who are at risk of  
27 complications, for example because of a physical or cognitive impairment,  
28 see [recommendation 1.7.9 in the NICE guideline on urinary incontinence](#)  
29 [and pelvic organ prolapse](#).

For a short explanation of why the committee made these recommendations see the [rationale and impact section on intravaginal devices and pessaries](#).

Full details of the evidence and the committee's discussion are in [evidence review N: physical devices](#).

## 1 Psychological interventions

2 1.6.28 Discuss the psychological impact of their symptoms with women who  
3 have pelvic floor dysfunction. Take account of this impact when  
4 developing a management plan.

5 1.6.29 For more guidance on psychological management, see the NICE  
6 guidelines on:

- 7 • [antenatal and postnatal mental health](#)
- 8 • [depression in adults with a chronic physical health problem](#).

For a short explanation of why the committee made these recommendations see the [rationale and impact section on psychological interventions](#).

Full details of the evidence and the committee's discussion are in [evidence review O: psychological interventions](#).

## 9 Behavioural approaches

10 1.6.30 Offer supported bladder retraining (combined with other interventions,  
11 such as pelvic floor muscle training) to women with urinary frequency,  
12 urgency or mixed incontinence.

13 1.6.31 For women with faecal incontinence, see the [section on diet, bowel habit  
14 and toilet access in the NICE guideline on faecal incontinence in adults](#).

15 1.6.32 When choosing a behavioural intervention, take into account that  
16 prompted toileting and habit training may be particularly suitable for  
17 women with cognitive impairment.

For a short explanation of why the committee made these recommendations see the [rationale and impact section on behavioural approaches](#).

Full details of the evidence and the committee's discussion are in [evidence review P: behavioural approaches](#).

## 1 Medicines

2 1.6.33 Do not offer vaginal diazepam to treat pelvic floor dysfunction, even for  
3 women with high muscle tone.

4 1.6.34 For guidance on medicines for urinary incontinence and faecal  
5 incontinence associated with pelvic floor dysfunction, see the [NICE](#)  
6 [guideline on urinary incontinence and pelvic organ prolapse in women](#) and  
7 the [NICE guideline on faecal incontinence in adults](#).

For a short explanation of why the committee made these recommendations see the [rationale and impact section on medicines](#).

Full details of the evidence and the committee's discussion are in [evidence review Q: pharmacological interventions](#).

## 8 Recommendations for research

9 The guideline committee has made the following recommendations for research.

### 10 Key recommendations for research

#### 11 1 How to provide pelvic floor muscle training

12 What is the most effective way to provide pelvic floor muscle training (covering the  
13 type of training, the timing, and who should supervise it), to improve adherence and  
14 prevent pelvic floor dysfunction?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on pelvic floor muscle training for preventing pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review F: pelvic floor muscle training to prevent pelvic floor dysfunction](#).

1

2 **2 Pelvic floor muscle training for preventing pelvic floor dysfunction in**  
3 **children and young women**

4 Is pelvic floor muscle training for children and young women (between 12 and  
5 17 years) effective in preventing pelvic floor dysfunction?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on pelvic floor muscle training for preventing pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review F: pelvic floor muscle training to prevent pelvic floor dysfunction](#).

6 **3 Pelvic floor muscle training for preventing pelvic floor dysfunction**  
7 **during pregnancy for women in higher-risk groups**

8 How effective is pelvic floor muscle training in preventing pelvic floor dysfunction  
9 during pregnancy in women who are in higher-risk groups?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on pelvic floor muscle training for preventing pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review F: pelvic floor muscle training to prevent pelvic floor dysfunction](#).

10 **4 Lifestyle factors to reduce the risk of pelvic floor dysfunction**

11 What lifestyle factors reduce the risk of developing pelvic floor dysfunction (for  
12 example diet, reducing carbonated drink and caffeine intake)?



For a short explanation of why the committee made this recommendation see the [rationale and impact section on exercise and diet](#).

Full details of the evidence and the committee's discussion are in [evidence review E: lifestyle factors for the prevention of pelvic floor dysfunction](#).

1

## 2 **5 Prediction tools**

3 What is the effectiveness of prediction tools for identifying women who are at risk of  
4 pelvic floor dysfunction?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on tools to predict pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review D: prediction tools](#).

## 5 **6 Pelvic floor muscle training for preventing pelvic floor dysfunction in 6 older women**

7 Is pelvic floor muscle training effective in preventing pelvic floor dysfunction for older  
8 women (over the age of 60), and women in the perimenopausal or postmenopausal  
9 phases?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on pelvic floor muscle training for preventing pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review F: pelvic floor muscle training to prevent pelvic floor dysfunction](#).

## 10 **7 Co-existing long-term conditions**

11 What co-existing long-term conditions (for example chronic respiratory disorders) are  
12 associated with a higher risk of pelvic floor dysfunction?

For a short explanation of why the committee made these recommendations see the [rationale and impact section on risk factors for pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review C: co-existing conditions](#).

1 **Other recommendations for research**

2 **Lifestyle factors to reduce the risk or pelvic floor dysfunction**

3 What are the long-term effects of different types, intensities and frequencies of  
4 exercise for preventing symptoms associated with pelvic floor dysfunction?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on exercise and diet](#).

Full details of the evidence and the committee's discussion are in [evidence review E: lifestyle factors for the prevention of pelvic floor dysfunction](#).

5 **Universal postnatal pelvic floor muscle training for preventing pelvic  
6 floor dysfunction**

7 Is universal postnatal pelvic floor muscle training effective in preventing pelvic floor  
8 dysfunction?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on pelvic floor muscle training for preventing pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review F: pelvic floor muscle training to prevent pelvic floor dysfunction](#).

9 **Pelvic floor muscle training for preventing bowel symptoms associated  
10 with pelvic floor dysfunction**

11 How effective is pelvic floor muscle training in preventing bowel symptoms  
12 associated with pelvic floor dysfunction?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on pelvic floor muscle training for preventing pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review F: pelvic floor muscle training to prevent pelvic floor dysfunction](#).

## 1 **Weight loss for managing pelvic floor dysfunction**

- 2 Can weight loss reduce symptoms of pelvic floor dysfunction in women who are
- 3 overweight or obese?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on weight loss](#).

Full details of the evidence and the committee's discussion are in [evidence review J: weight loss interventions](#).

## 4 **Diet for managing pelvic floor dysfunction**

- 5 What changes in diet can improve symptoms associated with pelvic floor
- 6 dysfunction?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on diet](#).

Full details of the evidence and the committee's discussion are in [evidence review K: dietary factors](#).

## 7 **Weight training to improve symptoms of pelvic floor dysfunction**

- 8 How effective is weight training at improving symptoms associated with pelvic floor
- 9 dysfunction?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on exercise](#).

Full details of the evidence and the committee's discussion are in [evidence review L: physical activity](#).

**1 Unsupervised exercise to improve symptoms of pelvic floor dysfunction**

- 2 How effective is unsupervised exercise (such as walking or swimming) at improving  
3 symptoms associated with pelvic floor dysfunction?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on exercise](#).

Full details of the evidence and the committee's discussion are in [evidence review L: physical activity](#).

**4 Psychological interventions to manage symptoms of pelvic floor  
5 dysfunction**

- 6 How effective are psychological interventions (either on their own or combined with  
7 other interventions) in the management of pelvic floor dysfunction?

For a short explanation of why the committee made this recommendation see the [rationale and impact section on psychological interventions](#).

Full details of the evidence and the committee's discussion are in [evidence review O: psychological interventions](#).

**8 Raising awareness about pelvic floor dysfunction**

- 9 Are community-based strategies effective in raising awareness about the prevention  
10 of pelvic floor dysfunction?

For a short explanation of why the committee made these recommendations see the [rationale and impact section on raising awareness of pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review A: raising awareness of pelvic floor dysfunction](#).

1 **Information valued by children and young women with pelvic floor**  
2 **dysfunction**

3 What are the experiences and information needs of children and young women  
4 (between 12 and 17 years) with pelvic floor dysfunction?

For a short explanation of why the committee made these recommendations see the [rationale and impact section on communicating and providing information to women with pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review G: information valued by women](#).

5 **Effective ways of supporting women to start and continue interventions**  
6 **for pelvic floor dysfunction**

7 What is the best way to support women to start and continue interventions for pelvic  
8 floor dysfunction (for example apps, decision aids, or behavioural change  
9 techniques)?

For a short explanation of why the committee made these recommendations see the [rationale and impact section on communicating and providing information to women with pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review H: effective ways of providing information](#).

10 **Effective ways of providing information to women with pelvic floor**  
11 **dysfunction**

12 What are best ways to provide information about pelvic floor dysfunction to children  
13 and young women (between 12 and 17 years), and to groups defined by protected  
14 characteristics under the Equality Act?

For a short explanation of why the committee made these recommendations see the [rationale and impact section on communicating and providing information to women with pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review H: effective ways of providing information](#).

**1 Medicines for pelvic floor dysfunction**

2 Is vaginal oestrogen effective at treating the symptoms of pelvic floor dysfunction?

For a short explanation of why the committee made these recommendations see the [rationale and impact section on medicines](#).

Full details of the evidence and the committee's discussion are in [evidence review Q: pharmacological interventions](#).

**3 Community-based multidisciplinary pelvic floor dysfunction teams**

4 What roles are needed in a community-based multidisciplinary pelvic floor  
5 dysfunction team?

For a short explanation of why the committee made these recommendations see the [rationale and impact section on community based multidisciplinary teams](#).

Full details of the evidence and the committee's discussion are in [evidence review R: community based multidisciplinary teams](#).

**6 Intravaginal devices and pessaries combined with pelvic floor muscle  
7 training for managing pelvic floor dysfunction**

8 How effective is a pessary or intravaginal device combined with pelvic floor muscle  
9 training for managing pelvic floor dysfunction, compared with pelvic floor muscle  
10 training alone?

For a short explanation of why the committee made these recommendations see the [rationale and impact section on pelvic floor muscle training for managing pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review M: pelvic floor muscle training for management of pelvic floor dysfunction](#).

1 **Virtual and in-person contact time for pelvic floor muscle training**

2 How effective is virtual contact with a trainer, compared with in-person contact, for  
3 pelvic floor muscle training?

For a short explanation of why the committee made this research recommendation see the [rationale and impact section on pelvic floor muscle training for managing pelvic floor dysfunction](#).

Full details of the evidence and the committee's discussion are in [evidence review M: pelvic floor muscle training for management of pelvic floor dysfunction](#).

4 **Anal plug devices and rectal irrigation for the management of bowel**  
5 **symptoms in women with pelvic floor dysfunction**

6 How effective are anal plug devices and rectal irrigation for bowel symptoms in  
7 women with pelvic floor dysfunction?

For a short explanation of why the committee made this research recommendation see the [rationale and impact section on intravaginal devices and pessaries](#).

Full details of the evidence and the committee's discussion are in [evidence review N: physical devices](#).

8

9 **Rationale and impact**

10 These sections briefly explain why the committee made the recommendations and  
11 how they might affect practice. They link to details of the evidence and a full  
12 description of the committee's discussion.

## 1 **Raising awareness of pelvic floor dysfunction for all women**

2 Recommendations [1.1.1 to 1.1.10](#)

### 3 **Why the committee made the recommendations**

4 The evidence was limited to 1 study, so most of the recommendations were based  
5 on the committee's knowledge and experience. However, this study did show that  
6 teaching pelvic floor health in school improved young women's understanding of  
7 their pelvic floor anatomy.

8 Improving women's knowledge of pelvic floor health is important because this  
9 increases the chance they will take action to prevent pelvic floor dysfunction (for  
10 example, through lifestyle changes and pelvic floor muscle training). The range of  
11 communication formats and strategies recommended is broad, because pelvic floor  
12 dysfunction can happen to any woman, so different strategies will be more effective  
13 for different groups of women. The committee discussed what the content of this  
14 information should be and decided that this would need to be tailored to the  
15 individual and the situation in which it is provided (for example, they noted that  
16 information provided during school lessons would likely have a different focus to  
17 information provided at a local community group). However, to ensure information is  
18 accurate and useful, it should include the topics highlighted in recommendation  
19 1.1.1. The committee acknowledged that there can be groups of women that  
20 experience inequalities (for example in access to services). When there is evidence  
21 of this, the committee noted that local authorities should consider designing  
22 information programmes that increase awareness of the condition, with the aim of  
23 advancing equality in healthcare provision and fostering good relations with  
24 communities.

25 The committee believed it was particularly important to raise awareness in maternity  
26 services, this is when symptoms can first occur, when risk factors can be identified  
27 and when prevention strategies can be started. The recommendations could lead to  
28 midwives providing information about pelvic floor dysfunction many times during a  
29 woman's pregnancy. However, the committee believe this is reasonable, because it  
30 gives the midwife an opportunity to normalise the topic and time to discuss it in  
31 detail. Normalisation is important, because embarrassment often gets in the way of



1 discussions about pelvic floor dysfunction. The committee also noted that frequent  
2 discussions would reinforce the message and improve adherence to prevention or  
3 management, which is key to their effectiveness.

4 Because of the sparsity of evidence, and the potential benefits of raising awareness  
5 of pelvic floor dysfunction, the committee made a [research recommendation](#) on this  
6 topic.

## 7 **How the recommendations might affect practice and services**

8 Pelvic floor dysfunction is not currently covered in the school curriculum. However,  
9 sex and relationship education is already a compulsory part of the curriculum, and  
10 pelvic floor dysfunction could be covered as part of these classes.

11 [Return to recommendations](#)

## 12 **Risk factors for pelvic floor dysfunction**

13 Recommendations. [1.2.1 \(box 1\) and 1.2.2](#)

## 14 **Why the committee made the recommendations**

15 Interpreting the evidence was difficult, because there was a lot of variation in how the  
16 studies were conducted, the way risk factors were defined, and which symptom each  
17 risk factor affected. However, the evidence did consistently reflect the committee's  
18 experience.

19 The evidence suggested a number of modifiable and non-modifiable risk factors. The  
20 committee recommended advising women of these, so they are aware of their risks  
21 and (for modifiable factors) can take steps to reduce them.

22 While some risk factors are non-modifiable (such as age or familial history), the  
23 committee agreed that it is still useful for women to be told about these. This is  
24 because if women know about their risks, they may be encouraged to reduce any  
25 modifiable risk factors and use preventative interventions (such as pelvic floor  
26 muscle training). Women with some of these risk factors will also be offered  
27 supervised pelvic floor muscle training (see the [recommendations on pelvic floor](#)  
28 [muscle training](#)).

## 1 **Co-existing conditions**

2 There was evidence for a variety of physical co-existing conditions associated with  
3 pelvic floor dysfunction. There was variation in the quality of the evidence because in  
4 some studies the inclusion criteria were not clearly described. In addition, while  
5 some conditions were shown to increase the risk of pelvic floor dysfunction, there  
6 was uncertainty around how large this increase is. Because of this, the committee  
7 did not list every condition identified in the studies. Instead, they highlighted the  
8 conditions that have a direct impact on the pelvic floor muscles, where the risk of  
9 pelvic floor dysfunction in the evidence aligns with their own experience.

10 For some conditions that may increase the risk of pelvic floor dysfunction (such as  
11 hypermobility, neurological disease and mental health problems), there was little  
12 evidence on their effect. In addition, there was only limited evidence on the effect of  
13 respiratory disease and chronic cough on the full range of symptoms, and this is  
14 particularly important because of the COVID-19 pandemic. A [research](#)  
15 [recommendation](#) was made to address these evidence gaps.

## 16 **Tools to predict pelvic floor dysfunction**

17 There are groups of women who have an increased risk of developing pelvic floor  
18 dysfunction. There are also interventions that can help prevent pelvic floor  
19 dysfunction (see the sections on [exercise and diet](#) and [pelvic floor muscle training](#)).  
20 Because of this, it would be useful to have an effective tool for predicting pelvic floor  
21 dysfunction so that women at higher risk can be prioritised for pelvic floor muscle  
22 training programmes. However, there was no evidence on the effectiveness of  
23 existing tools. The committee agreed this was an important area for further study,  
24 and made a [research recommendation on prediction tools](#).

## 25 **How the recommendations might affect practice**

26 The recommendations will standardise the information and advice that is provided to  
27 women, to enable better shared decision making. There are no significant costs  
28 associated with this, because providing information is already standard practice. The  
29 costs of the time taken to give this information would be outweighed by better  
30 satisfaction with services and the potential for avoiding future pelvic floor  
31 dysfunction.

1 [Return to recommendations](#)

## 2 **Exercise and diet and other modifiable risk factors**

3 Recommendations [1.3.1 to 1.3.7](#)

### 4 **Why the committee made the recommendation**

5 The evidence suggested that exercise, healthy diet and appropriate fluid intake help  
6 to prevent pelvic floor dysfunction. The quality of the evidence was low because  
7 some studies did not account for other factors that could potentially explain the  
8 findings. However, it reflected the committee's experience in clinical practice and  
9 was in line with standard UK diet and exercise guidance.

10 One of the risk factors for pelvic floor dysfunction is constipation, and in the  
11 committee's experience this can be addressed by adjusting fluid intake. Public health  
12 guidance does not clearly define ideal levels of fluid intake, and there are differences  
13 in the fluid needs of individuals (for example, people need more fluid if they are doing  
14 a lot of exercise). The committee therefore decided not to give their own definition of  
15 appropriate fluid intake.

16 The committee recognised that there were other modifiable risk factors, body mass  
17 index (BMI) over 25 kg/m<sup>2</sup>, smoking and diabetes and referenced relevant NICE  
18 guidance for management strategies for these which would help prevent pelvic floor  
19 dysfunction.

20 There was only limited evidence on specific dietary factors, such as caffeine and  
21 carbonated drinks. To address this, the committee made a [research](#)  
22 [recommendation](#).

23 No evidence was found on the impact of other lifestyle factors that can prevent  
24 symptoms associated with pelvic floor dysfunction (such as pelvic organ prolapse,  
25 emptying disorders of the bladder or bowel, sexual dysfunction, or chronic pelvic  
26 pain syndromes). However, in the committee's experience, exercise that involves  
27 repetitive pelvic floor loading (such as weight training) can improve pelvic floor  
28 muscle strength and so prevent symptoms. The committee agreed that more  
29 research is needed to support this, particularly in relation to the intensity of exercise  
30 needed, so they made a [research recommendation](#).

## 1 **How the recommendations might affect practice**

2 Currently, lifestyle advice is given to women to help with the management of  
3 symptoms of pelvic floor dysfunction. However, lifestyle advice is rarely considered  
4 as part of pelvic floor dysfunction prevention, because these women are symptom  
5 free. Therefore, these recommendations will help standardise the advice women  
6 receive on preventing pelvic floor dysfunction.

## 7 [Return to recommendations](#)

## 8 **Pelvic floor muscle training for preventing pelvic floor dysfunction**

9 Recommendations [1.3.8 to 1.3.15](#)

## 10 **Why the committee made the recommendations**

11 The available evidence covered women in 3 settings: community, antenatal, and  
12 postnatal. It specifically addressed pelvic floor dysfunction and associated symptoms  
13 (including urinary incontinence, pelvic organ prolapse and sexual dysfunction).

14 In addition to the research evidence, the committee also took account of the  
15 [Independent Medicine and Medical Devices Safety Review](#) and the [NHS Long Term](#)  
16 [Plan](#), which made recommendations on pelvic floor muscle training.

17 Pelvic floor muscle training was shown to prevent symptoms of pelvic floor  
18 dysfunction in all 3 settings. Evidence was not available for some symptoms (such  
19 as faecal incontinence and pelvic pain). The training was most effective in the short  
20 term. The committee noted that most studies looked at pregnant women (antenatal  
21 and postnatal). However, all healthcare professionals can provide encouragement to  
22 all women doing pelvic floor muscle training in all settings. Since there are particular  
23 obstetric risk factors associated with pelvic floor dysfunction (see the [section on risk](#)  
24 [factors for pelvic floor dysfunction](#)), pelvic floor muscle training could be particularly  
25 beneficial for pregnant women. The evidence supported this, because pelvic floor  
26 muscle training was shown to be effective in preventing pelvic floor symptoms when  
27 started during or after pregnancy.

28 Most of the evidence was for a narrow age range of women in their twenties or  
29 thirties. However, there was a consistent pattern of risk reduction across this group.

1 The committee believed that this supported them in making recommendations for  
2 women of all ages.

3 An economic analysis showed that supervised pelvic floor muscle training is likely to  
4 be cost effective for some groups of pregnant women. In particular, women who  
5 have a first-degree relative with pelvic floor dysfunction are at particularly high risk,  
6 so will see the most benefit relative to the cost of the training. The committee also  
7 identified 3 risk factors related to labour that they thought would pose the highest  
8 risk. They did not include 'an active second-stage labour taking more than 1 hour' in  
9 this recommendation because it is quite common (so would have a high potential  
10 cost), and the evidence on this was inconsistent (some studies showing an  
11 increased risk when labour was longer than 1 hour, but others did not show  
12 increased risk when it was longer than 20 minutes).

13 In all the studies, pelvic floor muscle training was supervised by a trained healthcare  
14 professional. The committee agreed that this is important for ensuring that pelvic  
15 floor muscle contraction is done correctly. In their experience, it is also important to  
16 tailor the training for each woman, to ensure that the exercises are manageable.

17 There was limited evidence on long-term effectiveness, as only 2 studies had a  
18 longer follow-up period (12 months in 1 study and 8 years in the other). However, all  
19 the studies showed that adherence decreased over time. In the committee's  
20 experience, continuing with the training is key for continued prevention of symptoms,  
21 and they agreed that low long-term adherence is likely to explain the limited  
22 evidence for long-term effectiveness. To address adherence problems, the  
23 committee made the recommendation on encouraging women to continue pelvic  
24 floor muscle training.

25 The committee made research recommendations to investigate several gaps in the  
26 evidence:

- 27
- 28 • [Most effective ways to provide training](#): the studies did not give much detail on  
29 how training should be conducted.
  - 30 • [Younger women](#): there was no evidence on training for young women (between  
31 12 and 17 years).
  - [Older women](#): there was only 1 study supporting training for women over 60.

- 1 • [Women who are pregnant and at particular risk of pelvic floor dysfunction](#): there  
2 was little evidence specific to women who are pregnant and have particular risk  
3 factors.
- 4 • [Faecal incontinence and emptying disorders of the bowel](#): there was no evidence  
5 on whether pelvic floor muscle training improves these symptoms (which can be  
6 particularly distressing).

7 The Independent Medicine and Medical Devices Safety Review recommended ‘that  
8 the NHS adopts the French model for universal postnatal pelvic floor rehabilitation’,  
9 to help prevent pelvic floor dysfunction. This model includes 10 sessions of routinely  
10 prescribed perineal rehabilitation sessions (pelvic floor muscle training with manual  
11 internal techniques, biofeedback and electrical stimulation) starting at least 8 weeks  
12 after birth, regardless of symptoms. The committee did not think the evidence (in  
13 particular the cost-effectiveness evidence) was strong enough to support this for all  
14 women during or after pregnancy. Instead, they identified the risk factors that put  
15 women at the greatest risk, for which pelvic floor training was most likely to be cost  
16 effective. They also made a [research recommendation](#) to investigate further.

### 17 **How the recommendations might affect practice**

18 Currently, pelvic floor muscle training is rarely used for prevention, and is usually  
19 only considered and taught to women when they develop symptoms (such as urinary  
20 incontinence). Therefore, the recommendations for pregnant women with family  
21 history of pelvic floor dysfunction or other risk factors are likely to have a significant  
22 resource impact (particularly given the size of the population who would be eligible).  
23 Some of this cost is likely to be offset by savings from preventing or delaying pelvic  
24 floor dysfunction.

25 Pregnant women receive information on pelvic floor muscle training. However, this is  
26 usually general advice rather than specific instructions or supervised sessions.

27 Women are not routinely told about how pelvic floor muscle training can help prevent  
28 sexual dysfunction during and after pregnancy. The recommendations ensure that all  
29 women are getting information on the benefits of pelvic floor muscle training to  
30 prevent pelvic floor dysfunction. This will standardise practice.

31 [Return to recommendations](#)

## 1 **Communicating and providing information to women with pelvic** 2 **floor dysfunction**

3 Recommendations [1.4.1 to 1.4.7](#)

### 4 **Why the committee made the recommendations**

5 Qualitative evidence showed that women with pelvic floor dysfunction perceived  
6 some communication styles as unhelpful. It also indicated that some women are not  
7 given enough information to understand their symptoms, diagnosis, investigations or  
8 treatment. The quality of the evidence was mixed, due to concerns about  
9 methodological limitations in the design of the studies. The committee also made  
10 recommendations based on their own experience, in areas where there was no  
11 evidence (such as video and telephone consultations).

12 The recommendation on asking women if they want their family, carers or other  
13 people involved is particularly important for addressing potential barriers to support  
14 for women with cognitive impairments.

15 Pelvic floor dysfunction is a complex condition, with particular communication issues  
16 (such as embarrassment). Based on the evidence and on their experience, the  
17 committee highlighted key issues to take into account when discussing pelvic floor  
18 dysfunction with women.

19 Because of the COVID-19 pandemic, many services are being provided remotely. In  
20 the committee's experience, this has been well received by some women. A  
21 particular benefit of remote services can be reduced embarrassment (both for  
22 women and for healthcare professionals), which makes women more willing to  
23 discuss problems. However, even though this may be the case for some women, the  
24 committee acknowledged that it may be harder for the healthcare professional to  
25 identify whether symptoms may not be reported due to embarrassment during a  
26 remote consultation.

27 The committee made research recommendations in areas where there was no  
28 evidence:

- 1 • [effective ways of providing information for young women \(between 12 and](#)
- 2 [17 years\) and women with protected characteristics \(such as physical or learning](#)
- 3 [disabilities\)](#)
- 4 • [effective ways of supporting women to start and continue with interventions for](#)
- 5 [pelvic floor dysfunction](#)
- 6 • [information valued by children and younger women with symptoms of pelvic floor](#)
- 7 [dysfunction.](#)

## 8 **How the recommendations might affect practice**

9 Healthcare professionals already discuss pelvic floor dysfunction with women and  
10 provide information on this. However, the information given and how it is  
11 communicated can vary, and these recommendations will standardise the process.  
12 As the symptoms of pelvic floor dysfunction are often distressing and embarrassing,  
13 communication and sensitivity are very important for all healthcare professionals to  
14 ensure good care is provided.

15 Services already use translation services as needed to overcome communication  
16 barriers. However, there may be an impact in areas where video consultation or  
17 digital information aids are not currently available.

18 [Return to recommendations](#)

## 19 **Assessment in primary care**

20 Recommendations [1.5.1 to 1.5.7](#)

## 21 **Why the committee made the recommendations**

22 There are a number of signs and symptoms associated with pelvic floor dysfunction.  
23 However, there was no evidence on which assessments are needed in non-  
24 specialist care to identify these signs and symptoms. Because of this, the committee  
25 made recommendations based on their clinical expertise, highlighting the  
26 investigations they use in their practice and the most important signs and symptoms  
27 to look out for.

28 There was evidence that healthcare professionals may overlook symptoms of pelvic  
29 floor dysfunction in women who have recently given birth. The evidence also



1 highlighted that there are common misconceptions about pelvic floor dysfunction  
2 during and after pregnancy, which can prevent women from seeking care early. To  
3 address this the committee emphasised that women who have recently given birth  
4 should be asked about symptoms.

5 In the committee's experience, many medications can impact on symptoms of pelvic  
6 floor dysfunction. In addition, this impact is often larger for people who are taking  
7 multiple medicines. Because of this, a medication review is important.

8 A focused history is important for identifying the likely cause of any symptoms,  
9 because many of the symptoms of pelvic floor dysfunction can be caused by other  
10 conditions as well.

11 The committee highlighted some of the examinations that would be needed to clarify  
12 whether symptoms are likely to be associated with pelvic floor dysfunction or not.

### 13 **How the recommendations might affect practice**

14 Pelvic floor dysfunction is a complex condition, and there is currently variation in how  
15 it is assessed. These recommendations will ensure consistency in the initial  
16 assessments that are performed in primary care.

17 [Return to recommendations](#)

### 18 **Community-based multidisciplinary teams**

19 Recommendation [1.6.1 to 1.6.3](#)

### 20 **Why the committee made the recommendations**

21 There was limited evidence on team-based approaches for managing pelvic floor  
22 dysfunction. However, the available evidence reflected the committee's experience  
23 in practice. They decided that the range of competencies needed could not be  
24 covered by one healthcare professional alone, and so a multidisciplinary team  
25 approach should be considered. This team would need to be community-based, to  
26 ensure it is accessible to all women with pelvic floor dysfunction.

1 Adherence and satisfaction with care are important factors in effective management  
2 of pelvic floor dysfunction, and the committee agreed that these would also be  
3 improved by community-based multidisciplinary teams.

4 The experience and training of multidisciplinary team members is likely to vary  
5 widely in different areas. Because of this, the committee made a recommendation on  
6 competencies, based on their own experience of the key knowledge and experience  
7 that is needed in the team to implement the other recommendations in this guideline.

8 The committee did not recommend including specific roles (such as specialist  
9 incontinence nurses) in the team, because community healthcare professionals can  
10 be trained to carry out non-specialist assessment, and because including specific  
11 specialists in every team could have substantial costs.

12 When agreeing a management plan it is important to involve the woman with pelvic  
13 floor dysfunction, to ensure the plan takes account of her needs and preferences.

#### 14 **How the recommendations might affect practice**

15 Community-based multidisciplinary teams may represent a change to current  
16 practice, because there is variation in their availability. Pelvic floor dysfunction is a  
17 common condition, and other services (such as community-based continence  
18 services) could form the basis of these teams. The committee decided that the  
19 benefits of good pelvic floor dysfunction management would outweigh potential costs  
20 associated with setting up community-based multidisciplinary teams.

21 There is currently variation in the competencies that community-based  
22 multidisciplinary teams have on assessing and managing pelvic floor dysfunction.  
23 There would be upfront costs for training healthcare professionals in the  
24 competencies recommended in this guideline, but these costs would be outweighed  
25 by better long-term outcomes (improved identification of symptoms and better  
26 management as a result).

27 [Return to recommendations](#)

## 1 **Lifestyle changes**

### 2 **Encouraging women to make lifestyle changes**

3 Recommendation [1.6.4](#)

#### 4 **Why the committee made the recommendation**

5 The evidence showed that positive communication improves patient motivation and  
6 adherence to lifestyle changes. This was also consistent with the committee's  
7 experience. It can take time for women to see a benefit from lifestyle changes, so the  
8 committee believed it was important to emphasise encouraging and motivating  
9 women in the recommendation.

#### 10 **How the recommendation might affect practice**

11 All healthcare professionals communicate with women and this recommendation will  
12 raise awareness that this communication should not only be framed in a negative  
13 way but provide positive messages when appropriate.

14 [Return to recommendations](#)

## 15 **Weight loss**

16 Recommendations [1.6.5 to 1.6.8](#)

#### 17 **Why the committee made the recommendations**

18 The evidence showed that in women with a body mass index (BMI) over 30 kg/m<sup>2</sup>,  
19 weight loss helped with urinary incontinence and overactive bladder. In the  
20 committee's experience, weight exacerbates these symptoms by putting pressure on  
21 the pelvic floor muscles and organs, so weight loss will be particularly beneficial. The  
22 evidence did not show any effect from weight loss on symptoms of pelvic organ  
23 prolapse. However, the committee still believe that weight loss may be beneficial in  
24 the early stages of pelvic organ prolapse, because less weight would press on the  
25 pelvic organs and this could improve symptoms.

26 The committee recommended against delaying other management options until  
27 women have lost weight because:

- 1 • there was no evidence on the impact of weight loss for many symptoms of pelvic  
2 floor dysfunction **and**  
3 • there are other interventions that could benefit women with pelvic floor  
4 dysfunction.

5 As other NICE guidelines cover helping people to lose weight, the committee  
6 referred to these guidelines rather than making new recommendations on weight-  
7 loss interventions.

8 The committee made a [research recommendation](#) to address the lack of evidence on  
9 many symptoms associated with pelvic floor dysfunction.

## 10 **How the recommendations might affect practice**

11 Weight loss referral related to pelvic floor dysfunction differs across the country. The  
12 recommendations would reduce variation and promote consistency in care.

## 13 [Return to recommendations](#)

### 14 **Diet**

15 Recommendations [1.6.9 and 1.6.10](#)

### 16 **Why the committee made the recommendations**

17 There was some evidence suggesting that reducing caffeine intake helps with  
18 urinary incontinence and overactive bladder, and this was supported by the  
19 committee's experience in practice.

20 No evidence was found on other symptoms associated with pelvic floor dysfunction.  
21 However, the committee agreed that in their experience, addressing fluid intake can  
22 help with symptoms by promoting an ideal stool consistency. Public health guidance  
23 does not clearly define ideal levels of fluid intake, and there are differences in the  
24 fluid needs of individuals (for example, people need more fluid if they are doing a lot  
25 of exercise). The committee therefore decided not give their own definition of  
26 appropriate fluid intake.

27 A balanced diet also reduces the risk of constipation and so would indirectly reduce  
28 the risk of pelvic floor dysfunction. This is particularly important for women with pelvic

1 organ prolapse, faecal incontinence, emptying disorders of the bowel and chronic  
2 pelvic pain syndromes.

3 The committee believed that more research specific to pelvic floor dysfunction  
4 related to food rather than fluid intake is needed, and made a [research](#)  
5 [recommendation](#) to address this.

## 6 **How the recommendations might affect practice**

7 These recommendations are in line with current clinical practice. Clinicians will  
8 already be familiar with the practical details of lifestyle changes that can be made to  
9 promote pelvic floor health, and lifestyle changes are a common aspect of  
10 management for symptoms of pelvic floor dysfunction.

11 [Return to recommendations](#)

## 12 **Exercise**

13 Recommendations [1.6.11 and 1.6.12](#)

## 14 **Why the committee made the recommendations**

15 There was some evidence on urinary incontinence, overactive bladder and pelvic  
16 organ prolapse. The evidence showed that exercise could improve these symptoms,  
17 but the exercise programmes in these studies were supervised and included pelvic  
18 floor muscle training as part of the interventions.

19 The physical activity interventions covered were yoga, pilates, weight training and  
20 aerobic exercises. However, it was not clear from the studies what type of exercises  
21 the women were doing, so the committee did not recommend specific exercises. The  
22 committee know from their own experience that women often ask whether physical  
23 activity could improve or worsen their symptoms. Because of the evidence that  
24 showed some improvement, they made a recommendation in favour of supervised  
25 exercise. 'Supervised' exercise is specified because certain exercises, if done  
26 incorrectly, can weaken the pelvic floor by increasing intra-abdominal pressure. This  
27 could worsen symptoms of pelvic floor dysfunction.

28 There is no evidence that unsupervised exercise improved or worsened symptoms of  
29 pelvic floor dysfunction. The committee acknowledged that there are general health

1 benefits associated with having an active lifestyle. Therefore, they also made a  
2 [research recommendation](#) on unsupervised activities (in particular, common  
3 exercises such as walking and swimming).

4 Heavy lifting has been considered a risk factor for damaging the pelvic floor by  
5 increasing intra-abdominal pressure. The [NICE guideline on urinary incontinence  
6 and pelvic organ prolapse in women](#) recommends minimising heavy lifting. However,  
7 a more recent study showed that weight training combined with pelvic floor muscle  
8 training could improve symptoms of urinary incontinence. Since there was  
9 uncertainty around the evidence and it was not entirely consistent with the  
10 committee's experience, they made a [research recommendation](#) to investigate this  
11 further.

## 12 **How the recommendation might affect practice**

13 The recommendation covers providing information, which is part of current practice,  
14 so there should be no cost to services. These recommendations will ensure women  
15 are educated on exercises they can do to improve their symptoms and those that are  
16 not harmful. In addition, the recommendations will standardise the information being  
17 provided.

## 18 [Return to recommendations](#)

## 19 **Pelvic floor muscle training for managing pelvic floor dysfunction**

20 Recommendations [1.6.13 to 1.6.20](#)

## 21 **Why the committee made the recommendations**

22 The evidence showed that pelvic floor muscle training improves several symptoms of  
23 pelvic floor dysfunction (pelvic organ prolapse, stress and mixed urinary  
24 incontinence, and faecal incontinence with co-existing pelvic organ prolapse). There  
25 was greater uncertainty around the findings on faecal incontinence with co-existing  
26 pelvic organ prolapse, because there was much less evidence in this area.

27 For pelvic organ prolapse, the evidence showed a benefit from pelvic floor muscle  
28 training for prolapse that does not extend beyond the hymen on straining. This

1 matched the committee's experience, as they agreed that more extensive pelvic  
2 organ prolapse would be managed in specialist care.

3 The recommended lengths of time for the training programmes are based on the  
4 most common time points used in the studies for assessing the benefit of training.  
5 This was 16 weeks for pelvic organ prolapse and faecal incontinence, and 3 months  
6 for urinary incontinence. The committee noted that this would give enough time to  
7 assess whether the training improved symptoms. This is also consistent with the  
8 [recommendations on pelvic floor muscle training in the NICE guideline on urinary](#)  
9 [incontinence and pelvic organ prolapse in women](#).

10 In addition to the research evidence, the committee also took account of [the](#)  
11 [Independent Medicine and Medical Devices Safety Review](#) and the [NHS Long Term](#)  
12 [Plan](#), which made recommendations on pelvic floor muscle training.

13 See the [rationale for pelvic floor muscle training for preventing pelvic floor](#)  
14 [dysfunction](#) for an explanation of the recommendations on supervising pelvic floor  
15 muscle training.

16 For additional therapies, such as weighted vaginal cones, biofeedback and electrical  
17 stimulation, the evidence was inconsistent. Some studies showed benefits, and  
18 others showed no effect. Some of the evidence suggested that these interventions  
19 could help women with pelvic floor muscle training by improving their ability to  
20 contract their pelvic floor muscles. In the committee's experience, effective pelvic  
21 floor contractions are important for improving pelvic floor dysfunction symptoms and  
22 that most women are able to do this as part of a supervised pelvic floor muscle  
23 training programme. However, the committee believed that supplementing pelvic  
24 floor muscle training programme with biofeedback, electrical stimulation or vaginal  
25 cones could be cost-effective in the subgroup who make little progress during  
26 supervised pelvic floor muscle training. These additional therapies are particularly  
27 likely to be cost effective if using them allows women to avoid the need for surgical  
28 intervention.

29 Based on their experience, the committee thought it would be important that women  
30 are advised to continue doing pelvic floor muscle training and that they have the  
31 opportunity to discuss progress in regular reviews during the initial training

1 programme. The committee believed that reviews with a healthcare professional  
2 improve adherence, which is important for the long-term effectiveness of pelvic floor  
3 muscle training.

4 There was some evidence suggesting that training in a group improved adherence  
5 and symptoms, but it was not consistently found to be more effective than individual  
6 training. This was supported by the committee's experience, as some women benefit  
7 from peer support while some feel more motivated with one-to-one supervision. To  
8 take account of this, the committee recommended giving women a choice of group  
9 or individual training. One-to-one supervision is more expensive than group training,  
10 but the difference in cost is relatively small and so the approach favoured by each  
11 woman is likely to be cost effective.

12 It was unclear whether using a pessary or intravaginal device would be effective  
13 when combined with pelvic floor muscle training, so the committee made a [research](#)  
14 [recommendation](#) for this. The development of remote clinical practice during the  
15 COVID-19 pandemic also made the committee curious about the effectiveness of  
16 virtual pelvic floor muscle training, so they [recommended research](#) into the  
17 effectiveness of this.

## 18 **How the recommendations might affect practice**

19 The recommendations will standardise practice. Pelvic floor muscle training is a key  
20 intervention for managing the symptoms of pelvic floor dysfunction and is already  
21 widely used in the NHS. However, access to group pelvic floor muscle exercise  
22 classes differs across the country. While some healthcare services may need to  
23 change practice, group pelvic floor muscle exercise classes are less expensive, so  
24 the committee did not anticipate a significant resource impact.

25 [Return to recommendations](#)

## 26 **Intravaginal devices and pessaries**

27 Recommendations [1.6.21 to 1.6.27](#)



## 1 **Why the committee made the recommendations**

2 The evidence on intravaginal devices was unclear, with variance across outcomes.  
3 For example, there was no measurable reduction in urinary leakage, but women  
4 reported that their symptoms improved. However, the committee noted that a  
5 subjective improvement in symptoms was still important, as it is an indication of the  
6 woman's perception of the device's success. The committee were also aware from  
7 their experience that these devices can help to prevent urinary leakage in certain  
8 circumstances (for example during exercise). Based on the limitations of the  
9 evidence and the potential complications, the committee recommended trialling  
10 intravaginal devices if other non-surgical options have been tried and have been  
11 unsuccessful, so that women could decide whether they were beneficial before using  
12 them long term.

13 This differs from [recommendation 1.4.23 in the NICE guideline on urinary](#)  
14 [incontinence and pelvic organ prolapse](#), which recommends against the use of  
15 intravaginal devices. However, the committee noted that recommendation 1.4.23 had  
16 not been updated since 2006. Most of the evidence they reviewed for this guideline  
17 has been published since 2006. Even though the findings from the evidence were  
18 not entirely certain, they decided that these devices should not be ruled out if other  
19 non-surgical options were unsuccessful. This would provide another option that may  
20 prevent the need for more invasive treatment.

21 The evidence on pessaries indicated that they help with symptoms of pelvic organ  
22 prolapse, and this is in keeping with the committee's clinical experience. However,  
23 there was a lack of long-term evidence on the effectiveness and potential  
24 complications of pessary use. Because of the uncertainty around pessaries, the  
25 committee specified particular benefits and harms to discuss with women, based on  
26 the evidence that was available and their clinical experience. This will help women to  
27 make an informed decision on whether a pessary is right for them.

28 In the committee's experience, women with physical or cognitive impairments may  
29 have difficulty in managing an intravaginal device or pessary and are at higher risk of  
30 complications. Because of this, these women should have regular appointments to  
31 check for complications. The committee also recommended telling women how to  
32 self-refer if they are managing the device themselves, so that they know how to get

1 help if they are having problems or if their intravaginal device or pessary does not  
2 help.

3 There was a lack of evidence on the physical devices available for managing faecal  
4 incontinence (which is a particularly distressing symptom). The existing evidence  
5 consists of studies in mixed populations of men and women, so it could not be used  
6 to make recommendations for the population of this guideline. To address this, the  
7 committee made a [research recommendation](#).

## 8 **How the recommendations might affect practice**

9 These recommendations are in line with current practice on pessaries. There is  
10 variation in the use of intravaginal devices, but the recommendations would not  
11 involve major changes to practice since it would be an option only if other options  
12 had not been successful. Even though this may increase the general use of  
13 intravaginal devices, they are already used in some areas. They may also prevent  
14 more invasive options (such as surgery) which are more costly.

15 [Return to recommendations](#)

## 16 **Psychological interventions**

17 Recommendations [1.6.28 and 1.6.29](#)

## 18 **Why the committee made the recommendations**

19 The evidence showed a psychological impact from the symptoms of pelvic floor  
20 dysfunction. However, the committee noted that there was a lot of uncertainty about  
21 this evidence and made recommendations based on their experience and expertise.  
22 They made a recommendation emphasising this because women with pelvic floor  
23 dysfunction often do not seek help with the psychological impact of their symptoms,  
24 and healthcare professionals do not always ask them about it.

25 Some therapies were shown to improve distress associated with pelvic floor  
26 dysfunction, but the studies were very small. There was also evidence that  
27 psychological therapy could help with vaginismus, but it was not clear from the  
28 studies whether the participants' symptoms were related to pelvic floor dysfunction.

1 The committee decided that they could not recommend therapies based on this  
2 evidence.

3 As other NICE guidelines cover identifying and managing mental health problems for  
4 people with a chronic health condition, the committee referenced these guidelines  
5 instead of making new recommendations on specific psychological interventions.

6 There was some evidence showing that psychological interventions improved  
7 attendance and adherence to pelvic floor muscle training. However, there were  
8 several limitations to this evidence:

- 9 • it did not show whether the improvement in attendance and adherence was  
10 sustained in the long term
- 11 • while some of the interventions improved the mental health of participants, it was  
12 not clear whether the interventions also had an impact on symptoms (which could  
13 mean that the improvement in mental health may not be sustained in the long  
14 term)
- 15 • the studies were small.

16 These limitations meant that the committee could not make a practice  
17 recommendation. However, they do believe that better attendance and adherence to  
18 training improves the benefit of pelvic floor muscle training. Because of this, they  
19 made a [research recommendation](#) on ways to improve adherence for women who  
20 are having this training.

## 21 **How the recommendations might affect practice**

22 The committee agreed that there is variation in practice in how well psychological  
23 factors related to pelvic floor dysfunction are considered when planning treatment.  
24 The recommendations would not involve major changes to practice, but would  
25 standardise current good practice.

26 [Return to recommendations](#)

## 27 **Behavioural approaches**

28 Recommendations [1.6.30 to 1.6.32](#)

## 1 **Why the committee made the recommendations**

2 There was evidence about behavioural techniques including bladder retraining and  
3 lifestyle education, provided under direct supervision by a trained healthcare  
4 professional. The studies usually included pelvic floor muscle training as part of the  
5 interventions. The symptoms covered in the studies included urinary incontinence,  
6 urinary urgency and frequency and faecal incontinence. Evidence was not available  
7 for some symptoms (such as emptying disorders of the bladder and bowel).

8 The evidence was difficult to interpret because there was variation in the quality of  
9 the research and a mixture of different interventions and comparators, which made it  
10 difficult to combine results. This meant that it was not clear which aspects of  
11 interventions were directly improving the symptoms of pelvic floor dysfunction.

12 The evidence showed that behavioural techniques in combination with pelvic floor  
13 muscle exercises improved these symptoms, which was in keeping with the  
14 committee's experience in clinical practice. The committee noted that bladder  
15 retraining consists of advice about when or how frequently to go to the toilet to  
16 encourage a routine that can help prevent incontinence episodes.

17 There was some limited evidence suggesting that a combination of behavioural  
18 techniques and pelvic floor muscle exercises was associated with improved  
19 adherence and satisfaction. The committee agreed that motivation and adherence  
20 were key to long-term benefit. The committee were conscious that behavioural  
21 techniques should be tailored to the individual, as ability may differ based on other  
22 co-existing conditions (such as cognitive impairment).

## 23 **How the recommendations might affect practice**

24 Behavioural techniques involve a wide range of techniques that can be used to  
25 change behaviour and teach women skills to reduce symptoms of pelvic floor  
26 dysfunction. These techniques are already used by most services, so the  
27 recommendations will reinforce current practice.

28 Bladder training can easily be provided in conjunction with a pelvic floor muscle  
29 training programme and would not add significant costs.

30 [Return to recommendations](#)

## 1 **Medicines**

2 Recommendations [1.6.33 and 1.6.34](#)

### 3 **Why the committee made the recommendations**

4 There was limited evidence on medicines for general pelvic floor dysfunction.  
5 However, the evidence available did show that intravaginal diazepam was not  
6 effective at improving symptoms. Although this evidence was based on a small  
7 population, the committee were also concerned about the risk of dependency from  
8 diazepam usage. Because of this risk and the lack of evidence for any benefit, the  
9 committee recommended against intravaginal diazepam.

10 The [NICE guidelines on urinary incontinence and pelvic organ prolapse in women](#)  
11 and [faecal incontinence in adults](#) make recommendations on medicines for  
12 symptoms that can be associated with pelvic floor dysfunction. The committee  
13 recommended following these recommendations for women with pelvic floor  
14 dysfunction, because the medicines recommended are likely to be effective even if  
15 the underlying cause of symptoms is different in the other guidelines.

16 Topical intravaginal oestrogen is currently used in clinical practice for managing  
17 pelvic floor dysfunction. However, no evidence was identified for this, so the  
18 committee made a [research recommendation](#).

### 19 **How the recommendations might affect practice**

20 The recommendation on intravaginal diazepam will not change current practice,  
21 since this is not currently used in the NHS. Since the other recommendation cross  
22 refers to other NICE guidance it will reinforce current guidance and will not have any  
23 significant resource impact.

24 [Return to recommendations](#)

## 25 **Context**

26 Pelvic floor dysfunction covers a variety of symptoms. In this guideline, the following  
27 symptoms are addressed as long as they are associated with pelvic floor  
28 dysfunction: urinary incontinence, emptying disorders of the bladder, faecal  
29 incontinence, emptying disorders of the bowel, pelvic organ prolapse, sexual

1 dysfunction and chronic pelvic pain syndromes. The 3 most common and definable  
2 conditions are urinary incontinence, faecal incontinence and pelvic organ prolapse.

3 Prevalence of pelvic floor dysfunction is high. For example, on examination prolapse  
4 is present in up to 50% of women. This can have a significant impact on quality of  
5 life, reducing social engagement and ability to exercise.

6 This guideline makes recommendations on common risk factors and on preventative  
7 interventions. Ideally, women who are most at risk of pelvic floor dysfunction would  
8 be identified early and offered interventions to prevent symptoms developing. This  
9 would reduce the impact on women and the NHS.

10 When pelvic floor dysfunction is diagnosed, there is variation in the availability of  
11 non-surgical management options, such as pelvic floor muscle training. Women have  
12 no clear and effective strategies available to prevent worsening of the condition. This  
13 guideline provides a more community-based pathway to address these problems  
14 and to reduce the number of women who develop complex symptoms that need  
15 specialist care (including surgery).

## 16 **Finding more information and resources**

17 To find NICE guidance on related topics, including guidance in development, see the  
18 NICE webpage on [gynaecological conditions](#) and [uterine prolapse](#).

19 © NICE 2021. All rights reserved. Subject to [Notice of rights](#).